Literatur
- 1
Murray A, Hagen N A.
Hydromorphone.
J Pain Symptom Manage.
2005;
29 (Suppl 5)
S57-S66
- 2
Güttler K, Sabatowski R.
Differential therapeutic aspects of analgesia with oral sustained-release strong opioids:
application intervals, metabolism and immunosuppression.
Schmerz.
2008;
22 (5)
562, 564-568, 570
- 3
Sarhill N, Walsh D, Nelson K A.
Hydromorphone: pharmacology and clinical applications in cancer patients.
Support Care Cancer.
2001;
9
84-96
- 4
Schwab M, Marx C, Zanger U. et al .
Pharmakogenetik der Zytochrom-P-450-Enzyme: Bedeutung für Wirkungen und Nebenwirkungen
von Medikamenten.
Dtsch Arztebl.
2002;
99
A-497–A-504
- 5
Gupta S, Satyhan G.
Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone
in the presence and absence of food.
J Pain Symptom Manage.
2007;
33
S19-S24
- 6
Sathyan G, Xu E, Thipphawong J. et al .
Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone
in the presence and absence of food.
BMC Clin Pharmacol.
2007;
7
2
- 7
Hale M, Tudor I C, Khanna S. et al .
Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release
oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results
of a 6-week, randomized, open-label, noninferiority analysis.
Clinical Therapeutics.
2007;
29
874-888
- 8
Sathyan G, Sivakumar K, Thipphawong J.
Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone
in the presence of alcohol.
Curr Med Res Opin.
2008;
24 (1)
297-305
Dr. med. Michael Zimmermann
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Schmerzambulanz,
Johann-Wolfgang-Goethe-Universität
Theodor-Stern-Kai 7
60590 Frankfurt/Main
Phone: ++ 49/69/6 30 15 8 70
Email: Michael.Zimmermann@kgu.de
